About Regatta
We are building the missing layer between biotech science and the markets that price it.
Regatta is a research company building prediction markets as a biotech service. The premise is simple: the events that move biotech valuations — regulatory decisions, clinical readouts, advisory committee votes — deserve calibrated probabilities, produced by forecasters who are paid only when they are right. We are building the platform that does that, and launching in August 2026.
Founded2026.
Team- Austin Co-founder, CEO
- Stephan Co-founder, Business Development
- Monica Co-founder, Operations
- Manish Engineering Lead
- Daniela Administration
All Regatta analysts are identity-verified, background-checked, and employment-monitored by Regatta. Some publish under pseudonym at their discretion. A conflict-prohibition list is enforced and updated quarterly, and personal trading restrictions are enforced via attestation. Full disclosures go live with the platform.
Get in touchFor partnership, press, or analyst inquiries, request access from the homepage and tell us who you are — we will route it to the right person.